Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas Therapeutics(US:CALT) Prnewswireยท2024-05-14 11:35"This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN," said Renee Aguiar-Lucander, CEO. Results from the Chinese subpopulation analysis of the Phase 3 NefIgArd trial, presented at the American Society of Nephrology (ASN) Kidney Week in 2023, provided evidence that the treatment effect of Nefecon in the Chinese cohort was gr ...